AstraZeneca Reports 7% Nine-Month Revenue Growth, Reiterates FY26 Guidance
Revenue for the nine months ended September 30 rose 7% to $46.88 billion. Reported EPS increased 10% to $5.62, while operating profit rose 10% to $11.80 billion and underlying earnings grew 11% to $16.70 billion.
Total revenues for the nine months ended 30 September increased 7% to $46.88bn, driven by $43.96bn of product sales and a 33% jump in alliance revenues, while reported EPS climbed 10% to $5.62, operating profits advanced 10% to $11.80bn and underlying earnings grew 11% to $16.70bn. Q3 revenues rose…